

Natalia Reixach

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6165000/publications.pdf>

Version: 2024-02-01

32
papers

2,136
citations

304743

22
h-index

395702

33
g-index

33
all docs

33
docs citations

33
times ranked

2808
citing authors

#	ARTICLE	IF	CITATIONS
1	Transthyretin deposition promotes progression of osteoarthritis. <i>Aging Cell</i> , 2017, 16, 1313-1322.	6.7	22
2	Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. <i>Nature Communications</i> , 2016, 7, 10787.	12.8	139
3	Transthyretin Deposition in Articular Cartilage: A Novel Mechanism in the Pathogenesis of Osteoarthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 2097-2107.	5.6	40
4	Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: insights into early events of non-fibrillar tissue damage. <i>Bioscience Reports</i> , 2015, 35, .	2.4	21
5	The Systemic Amyloid Precursor Transthyretin (TTR) Behaves as a Neuronal Stress Protein Regulated by HSF1 in SH-SY5Y Human Neuroblastoma Cells and APP23 Alzheimer's Disease Model Mice. <i>Journal of Neuroscience</i> , 2014, 34, 7253-7265.	3.6	47
6	Quantification of Quaternary Structure Stability in Aggregation-Prone Proteins under Physiological Conditions: The Transthyretin Case. <i>Biochemistry</i> , 2014, 53, 6496-6510.	2.5	28
7	Correction to Mutasynthesis of a Potent Anticancer Sibiromycin Analogue. <i>ACS Chemical Biology</i> , 2014, 9, 1214-1214.	3.4	1
8	Age-Related Oxidative Modifications of Transthyretin Modulate Its Amyloidogenicity. <i>Biochemistry</i> , 2013, 52, 1913-1926.	2.5	95
9	AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 9992-9997.	7.1	120
10	Mutasynthesis of a Potent Anticancer Sibiromycin Analogue. <i>ACS Chemical Biology</i> , 2012, 7, 973-977.	3.4	16
11	Sulfated Glycosaminoglycans Accelerate Transthyretin Amyloidogenesis by Quaternary Structural Conversion. <i>Biochemistry</i> , 2011, 50, 1001-1015.	2.5	89
12	Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs. <i>Biochemical and Biophysical Research Communications</i> , 2011, 410, 707-713.	2.1	85
13	Potent Kinetic Stabilizers That Prevent Transthyretin-Mediated Cardiomyocyte Proteotoxicity. <i>Science Translational Medicine</i> , 2011, 3, 97ra81.	12.4	61
14	Neuronal Production of Transthyretin in Human and Murine Alzheimer's Disease: Is It Protective?. <i>Journal of Neuroscience</i> , 2011, 31, 12483-12490.	3.6	105
15	Chemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasma. <i>Nature Chemical Biology</i> , 2010, 6, 133-139.	8.0	74
16	A Substructure Combination Strategy To Create Potent and Selective Transthyretin Kinetic Stabilizers That Prevent Amyloidogenesis and Cytotoxicity. <i>Journal of the American Chemical Society</i> , 2010, 132, 1359-1370.	13.7	67
17	Transthyretin: the servant of many masters. <i>Cellular and Molecular Life Sciences</i> , 2009, 66, 3095-3101.	5.4	164
18	Formation of cytotoxic transthyretin is not dependent on inter-molecular disulphide bridges commonly found within the amyloid form. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2008, 15, 240-245.	3.0	10

#	ARTICLE	IF	CITATIONS
19	Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of A β toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 2681-2686.	7.1	245
20	Human-Murine Transthyretin Heterotetramers Are Kinetically Stable and Non-amyloidogenic. Journal of Biological Chemistry, 2008, 283, 2098-2107.	3.4	48
21	<i>In vivo</i> stabilization of mutant human transthyretin in transgenic mice. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2007, 14, 227-236.	3.0	27
22	Cell based screening of inhibitors of transthyretin aggregation. Biochemical and Biophysical Research Communications, 2006, 348, 889-897.	2.1	36
23	Oxidation inhibits amyloid fibril formation of transthyretin. FEBS Journal, 2006, 273, 5400-5406.	4.7	41
24	Poly-(L-alanine) expansions form core β -sheets that nucleate amyloid assembly. Proteins: Structure, Function and Bioinformatics, 2005, 61, 579-589.	2.6	80
25	Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 2817-2822.	7.1	336
26	Successful identification of novel agents to control infectious diseases from screening mixture-based peptide combinatorial libraries in complex cell-based bioassays. Biopolymers, 2003, 71, 103-116.	2.4	7
27	The pathogenesis of transthyretin tissue deposition: lessons from transgenic mice. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2003, 10, 2-6.	3.0	17
28	Inhibition of β -Amyloid-Induced Neurotoxicity by Imidazopyridoindoles Derived from a Synthetic Combinatorial Library. Journal of Structural Biology, 2000, 130, 247-258.	2.8	36
29	Biotransformations of putative phytoecdysteroid biosynthetic precursors in tissue cultures of Polypodium vulgare. FEBS Journal, 1999, 266, 608-615.	0.2	16
30	Phytoecdysteroid overproduction in Polypodium vulgare prothalli. Phytochemistry, 1997, 46, 1183-1187.	2.9	12
31	Biosynthesis of ecdysteroids in in vitro prothalli cultures of Polypodium vulgare. Phytochemistry, 1996, 43, 597-602.	2.9	19
32	New ecdysteroids from Polypodium vulgare. Tetrahedron, 1994, 50, 7247-7252.	1.9	31